Key result
Thrombin-dependent PAR-1 activation induces vasculogenic mimicry in non-small-cell lung cancer, suggesting that future anticoagulant trials should stratify patients by thrombin and PAR-1 expression.
Answers are grounded in this paper and cite their sources.
This editorial highlights that thrombin-mediated vasculogenic mimicry in NSCLC could be targeted by combining anticoagulants with antiangiogenic therapy in patients stratified by thrombin and PAR-1 expression.
In a recent study published in Signal Transduction and Targeted Therapy , Dr. Zhao and colleagues 1 identify thrombin as a novel mediator of vasculogenic mimicry in non-small-cell lung cancer (NSCLC). This provides important mechanistic insight by which coagulation (factors) may drive tumor progression and several lessons to improve anticoagulant therapy of cancer patients can be learned from the paper.
No takes yet. Share an insight, caveat, or question.
C. Arnold Spek (2020) conducted an editorial in Non-small-cell lung cancer (NSCLC). Anticoagulant therapy (thrombin inhibition) was evaluated. Thrombin-dependent PAR-1 activation induces vasculogenic mimicry in non-small-cell lung cancer, suggesting that future anticoagulant trials should stratify patients by thrombin and PAR-1 expression.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: